When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Expert panel discusses innovating business models to take advantage of technologies that can improve how patients access and pay for care to maintain their health. Presenters: Nick Soman…
Venture capitalists give their take on investing during the pandemic and how they’re navigating the new, unique demand for digital health solutions. Presenters: Christopher Leuter – MIT Steve…
Panelists discuss the science, research, investment, and opportunities of psychedelic medicine for mental health. Presenters: Rick Doblin – MAPS Matthew Baggott – Co-founder & CEP of Tactogen Jennifer…
Judith L. Pearson, best-selling author of The Wolves at the Door: The True Story of America’s Greatest Female Spy, recently released her latest book – From Shadows to…
Pediatric surgeon and researcher Lorraine Kelley-Quon, MD, MSHS, FAAP, from Children’s Hospital Los Angeles, joins Healthy Skeptic, MD host Michael Hochman, MD, MPH, to discuss treatment of pain…
